Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables - Other: 2016-2023

Historic Receivables - Other for Fortress Biotech (FBIO) over the last 8 years, with Dec 2023 value amounting to $100,000.

  • Fortress Biotech's Receivables - Other fell 94.74% to $100,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $100,000, marking a year-over-year decrease of 94.74%. This contributed to the annual value of $100,000 for FY2023, which is 94.74% down from last year.
  • Latest data reveals that Fortress Biotech reported Receivables - Other of $100,000 as of FY2023, which was down 94.74% from $1.9 million recorded in FY2022.
  • Fortress Biotech's 5-year Receivables - Other high stood at $1.9 million for FY2022, and its period low was $100,000 during FY2023.
  • Its 3-year average for Receivables - Other is $1.2 million, with a median of $1.6 million in 2021.
  • Its Receivables - Other has fluctuated over the past 5 years, first increased by 18.75% in 2022, then crashed by 94.74% in 2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Other (Yearly) stood at $1.4 million in 2019, then climbed by 14.29% to $1.6 million in 2020, then remained steady at $1.6 million in 2021, then grew by 18.75% to $1.9 million in 2022, then crashed by 94.74% to $100,000 in 2023.